Intervention not reported
Serious adverse events (number of people) · people with liver cirrhosis and ascites
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious adverse events (number of events) · people with non‐alcohol‐related fatty liver disease (NAFLD)
It is very uncertain whether thiazolidinediones changes serious adverse events (number of events) compared with no intervention (very low certainty).
1 finding from 1 review
Serious adverse events (number of events) · people with non‐alcohol‐related fatty liver disease (NAFLD)
It is very uncertain whether antioxidants changes serious adverse events (number of events) compared with no intervention (very low certainty).
1 finding from 1 review
Serious adverse events (number of events) · people with non‐alcohol‐related fatty liver disease (NAFLD)
It is very uncertain whether bile acids changes serious adverse events (number of events) compared with no intervention (very low certainty).
1 finding from 1 review
Serious adverse events (number of events) · people with primary biliary cholangitis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious adverse events (number of events) · people with primary biliary cholangitis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious adverse events (number of events) · people with primary biliary cholangitis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious adverse events (number of events) · people with primary biliary cholangitis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious adverse events (number of events) · people with primary biliary cholangitis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious adverse events (number of events) · people with primary biliary cholangitis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious adverse events (number of events) · people with primary biliary cholangitis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious adverse events (number of events) · people with early‐ or very early‐stage hepatocellular carcinoma ineligible for surgery
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious adverse events (number of events) · people with early‐ or very early‐stage hepatocellular carcinoma ineligible for surgery
1 finding from 1 review
Serious adverse events (number of events) · people with early‐ or very early‐stage hepatocellular carcinoma ineligible for surgery
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious adverse events (number of events) · people with early‐ or very early‐stage hepatocellular carcinoma eligible for surgery
Surgery may leads to higher serious adverse events (number of events) compared with radiofrequency ablation (low certainty).
1 finding from 1 review
Serious adverse events (number of events) · people with early‐ or very early‐stage hepatocellular carcinoma ineligible for surgery
It is very uncertain whether percutaneous alcohol injection changes serious adverse events (number of events) compared with radiofrequency ablation (very low certainty).
1 finding from 1 review
Serious adverse events (number of events) · patients with laparoscopic cholecystectomy.
It is very uncertain whether routine abdominal drain changes serious adverse events (number of events) compared with 'no drain' (very low certainty).
1 finding from 1 review
Intervention not reported
Number of people with serious adverse events · people with dementia and mild to moderate pain
1 finding from 1 review
Intervention not reported
Number of serious adverse events ‐ pulmonary · treating infections in people with neutropenia or neutrophil dysfunction
It is very uncertain whether the intervention changes number of serious adverse events ‐ pulmonary (very low certainty).
1 finding from 1 review
Number of participants experiencing any serious adverse events · patients with osteoarthritis
It is very uncertain whether celecoxib changes number experiencing any serious adverse events compared with tNSAIDs (very low certainty).
1 finding from 1 review